Immune-related Adverse Events — CAR T-Cell Therapy

Publication Date: November 1, 2021

Key Points

Key Points

  • Immunotherapy has revolutionized the treatment of many different types of cancers.
  • Chimeric antigen receptor T-cell (CAR T) therapy, an expanding immunotherapeutic approach, modifies T cells to redirect them to eradicate malignant cells.
    • CAR T-cell therapy is regarded as a “living drug” since cells are expected to persist long term with efficacy that may last for decades.
  • CAR T-cell therapy is administered with a single infusion and close monitoring.
  • CAR T-cell therapy is associated with severe, even fatal, toxicities such as cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS).
    • The incidence of CRS has been reported to range from 57%–93%, and ICANS from 20%–70%, based on the agent used.

Key Recommendations

Key Recommendatio...

The following are general recommendations that sh...


...is recommended that clinicians manage toxicitie...


Management

...agement

...ommendations In patients with active infection,...


...ble 1. Cytokine Release Syndrome Rec...


...CANS RecommendationsHaving trouble view...


...emophagocytic Lymphohistiocytosis (HLH) Recommen...


...openias RecommendationsHaving trou...


...able 5. B-cell Aplasia Recommendations...


...6. Disseminated Intravascular Coagu...


...onsHaving trouble viewing table? Expand...


...ble 8. CAR T-cell TherapiesHaving trou...